全文获取类型
收费全文 | 2801篇 |
免费 | 250篇 |
国内免费 | 114篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 42篇 |
妇产科学 | 15篇 |
基础医学 | 166篇 |
口腔科学 | 22篇 |
临床医学 | 297篇 |
内科学 | 219篇 |
皮肤病学 | 13篇 |
神经病学 | 73篇 |
特种医学 | 312篇 |
外科学 | 135篇 |
综合类 | 409篇 |
预防医学 | 141篇 |
眼科学 | 55篇 |
药学 | 746篇 |
中国医学 | 271篇 |
肿瘤学 | 244篇 |
出版年
2024年 | 16篇 |
2023年 | 42篇 |
2022年 | 56篇 |
2021年 | 88篇 |
2020年 | 83篇 |
2019年 | 96篇 |
2018年 | 88篇 |
2017年 | 103篇 |
2016年 | 124篇 |
2015年 | 101篇 |
2014年 | 214篇 |
2013年 | 197篇 |
2012年 | 201篇 |
2011年 | 199篇 |
2010年 | 141篇 |
2009年 | 148篇 |
2008年 | 131篇 |
2007年 | 98篇 |
2006年 | 121篇 |
2005年 | 132篇 |
2004年 | 76篇 |
2003年 | 93篇 |
2002年 | 76篇 |
2001年 | 54篇 |
2000年 | 44篇 |
1999年 | 42篇 |
1998年 | 44篇 |
1997年 | 34篇 |
1996年 | 38篇 |
1995年 | 16篇 |
1994年 | 28篇 |
1993年 | 20篇 |
1992年 | 16篇 |
1991年 | 23篇 |
1990年 | 16篇 |
1989年 | 12篇 |
1988年 | 13篇 |
1987年 | 12篇 |
1986年 | 15篇 |
1985年 | 23篇 |
1984年 | 14篇 |
1983年 | 5篇 |
1982年 | 21篇 |
1981年 | 10篇 |
1980年 | 10篇 |
1979年 | 7篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1975年 | 7篇 |
1974年 | 3篇 |
排序方式: 共有3165条查询结果,搜索用时 15 毫秒
1.
通过对中医古籍中有关升降散论述的文献梳理,全面探讨其内涵。本方是在大黄、僵蚕为雏形的基础上增加蝉蜕、姜黄而成方,几经易名,终在杨璿《伤寒瘟疫条辨》中为后人所熟知。本方广泛用于治疗瘟疫,以丸剂、散剂为主,方便携带,便于服用;重用大黄旨在祛邪、逐秽;应用时视人之体质强弱和量其毒之轻重而判断用药多寡,并辅以米酒、生蜜等以顾护正气。杨璿将其由治疗“热疫”的专方扩展为治疗“表里三焦大热”的通用方剂,扩大了本方治疗疾病范围。 相似文献
2.
目的比较3%高渗盐水和20%甘露醇治疗重症动脉瘤性蛛网膜下腔出血所致颅内压增高的疗效.方法25例动脉瘤性蛛网膜下腔出血患者出现颅内压增高事件时, 随机交替接受等渗透剂量的160 mL 3%高渗盐水与150 mL 20%甘露醇进行降低颅内压治疗, 连续监测患者颅内压、平均动脉压、脑灌注压及中心静脉压.记录有效降低颅内压持续时间、颅内压最大降幅及其时间, 用药前及用药后1 h、3 h血钠水平及血浆渗透压.结果3%高渗盐水和20%甘露醇均可降低颅内压(均 P < 0.01), 两者的降低颅内压作用持续时间及颅内压降幅差异均无统计学意义(均 P >0.05).患者脑灌注压较用药前均上升(均 P < 0.01), 平均动脉压先上升后下降, 但差异无统计学意义( P >0.05).患者中心静脉压稍有波动, 但差异均无统计学意义(均 P >0.05).20%甘露醇治疗后患者血钠下降, 3%高渗盐水治疗后患者血钠值上升, 变化均有统计学意义(均 P < 0.05).20%甘露醇及3%高渗盐水治疗后患者血浆渗透压均先上升后下降, 变化均有统计学意义(均 P < 0.01). 结论3%高渗盐水可作为治疗动脉瘤性蛛网膜下腔出血所致颅内压增高患者的一线治疗药物. 相似文献
3.
Joshua Manghelli Lisa Brown Hany B. Tadros Nabil A. Munfakh 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(5):491-494
The inflammatory response induced by cardiopulmonary bypass decreases vascular tone, which in turn can lead to vasoplegic syndrome. Indeed the hypotension consequent to on-pump cardiac surgery often necessitates vasopressor and intravenous fluid support. Methylene blue counteracts vasoplegic syndrome by inhibiting the formation of nitric oxide.We report the use of methylene blue in a 75-year-old man who developed vasoplegic syndrome after cardiac surgery. After the administration of methylene blue, his hypotension improved to the extent that he could be weaned from vasopressors. The use of methylene blue should be considered in patients who develop hypotension refractory to standard treatment after cardiac surgery. 相似文献
4.
5.
6.
C. Caramella F. Ferrari M. C. Bonferoni M. E. Sangalli M. De Bernardi Di Valserra F. Feletti M. R. Galmozzi 《Biopharmaceutics & drug disposition》1993,14(2):143-160
Six preparations were considered: three multiple unit dosage forms (micropellets in capsules) (D, E and G) and one matrix tablet (B) were experimental prolonged release formulations, two non-disintegrating tablets (A and C) were commercial products. The in vitro dissolution behaviour of the differing formulations was investigated using the USP XXII paddle apparatus. The in vivo study was effected on a panel of 12 healthy volunteers. The two commercial tablets (A and C) showed mean dissolution time (MDT) of 1.34 and 1.44 h and td of 91 and 92 min, respectively; for prolonged release formulations (B, E, D, and G) MDT ranged between 2.28 and 4.23 h and td between 149 and 291 min. The mean residence time (MRT) was 8.68 and 6.47 h for tablets A and C, respectively; it ranged between 9.62 and 10.24 h for the multiple unit formulations E, D, and G and was 11.27 h for matrix B. Formulation B also showed the higher apparent elimination half-life t1/2 (7.12 h), while apparent t1/2 for all the other formulations were very similar, ranging between 5.04 and 5.28 h. High variability between the various formulations was found for Cmax and AUC values, and no relationships could be established with the type of formulation. An in vitro/in vivo correlation was found for all the formulations examined on the basis of analogous parameters (MDT and MRT); (r = 0.83, p <0.05). In a few cases the Wagner-Nelson deconvolution method was applied to individual plasma level versus time curves and the corresponding absorption curves were obtained. In these cases the in vitro/in vivo correlation was tested on the basis of the comparison of the in vivo absorption curves with the in vitro dissolution profiles. This was accomplished using the ‘Levy's plot’ (per cent released versus per cent absorbed) approach and provided further support for the correlation found. 相似文献
7.
采用模拟在人体中使用的实测超声剂量,对体外培养的L-929株细胞进行辐照,通过细胞回复能力试验,观察回复前后的细胞增殖与抑制。对体外培养的人胚肺纤维细胞经1次及5次辐照,观察了DNA及细胞核面积的影响。并通过电镜观察了细胞超微结构的变化。上述实验结果,均提示经辐照后细胞有增殖趋向 相似文献
8.
用Bayesian一点法拟合心衰病人的DG个体药物动力学参数及个体化给药方案,用minitab对软件DG群体药物动力学数据进行统计学分析.以CrCL为固定效应变量,建立系列回归模型,预测心衰病人的DG个体药物动力学参数、个体化给药方案及其对映的(?)ss.结果显示CrCL与DG群体药物动力学参数存在高度的相关(P<0.001),相关系数分别为:CL=0.805,Vd=0.985,T_(1/2)=-0.517,K=0.525,D_(1.0)=0.714.并建立定量回归模型,预测DG个体药物动力学参数,预测参数与实测参数没有统计学差异,其中以Vd预测精度最好,有95%的预测值在实测值的95%置信限以内.与实测值相关系数为0.974,估计标准误差小于3.3%;其次是CL,有2/3的预测值在实测值95%置信限以内,与实测值相关系数为0.797,估计标准误差小于20%;T_(1/2)和K预测结果稍差.CrCL预测的个体化给药方案80%符合最佳个体化给药方案,且两者所对应的(?)ss没有显著性差异. 相似文献
9.
饮水有机浓集物致突变活性影响因素的研究 总被引:4,自引:0,他引:4
本文探讨饮水有机物浓集流速及加氯量对致突变活性的影响。试验表明,饮水有机物浓集流速控制在每分钟2倍树脂柱床体积时,可获得最佳致突变效果。当加氯量≥20mg/L时,对TA98±S9和TA100—S9菌株有致突变活性,≤2mg/L时对TA98±S9和TA100±S9菌株无致突变活性。为最大限度减少致突变效应,在净水过程中保证流行病学安全前提下,减少加氯量和加氯次数是十分必要的。 相似文献
10.
Summary
The introduction of fast gradient systems allows a reliable visualization of the extracranial carotid vessels by the magnetic
resonance angiography (MRA) which meanwhile is implemented into clinical routine. By the mainly applied time-of-flight (TOF)
technique, vessels can be imaged without contrast agent (CA). Due to the application of ultra-fast gradient-echo-sequences,
the first-pass evaluation of an intravenous bolus-injection of Gadolinium in the carotids from the aortic arch up to the skull
base can be performed in less than 30 s. In this study, advantages and disadvantages of both techniques are discussed. For
a qualitatively optimal contrast enhanced MRA (CE-MRA) timing parameters like injection delay, flow rate and the adjustment
of sequence parameters have to be considered in relation to the fast venous return from the sinus to the jugular veins. First,
the optimal time point of the data acquisition have been determined at a model and with a computer simulation in reference
to the presence of CA in the arteries. As a result, 90 % of the contrast contribution is defined by 16 % of the symmetrically
acquired central k-space lines. A measuring protocol for clinical use was obtained by a gradual variation of spacial resolution,
measuring time and CA-injection parameters and was proved in normal volunteers and patients. An exact determination of the
bolus-arrival-time by means of a test-bolus injection was acquired. The best qualitative results were achieved by a double-dose
injection at 2 ml/s injection rate. The temporal reserves of ultra-fast sequences should be invested in the improvement of
the spatial resolution. To date, further investigations related to the problem of optimal CA-application may improve the potentials
of CE-MRA procedures.
相似文献